Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17265678 | 1.00 | LTA4H (0.52) | LTA4HCYSLTR2CYSLTR1MAPTBRD4 | |
| SCHEMBL16245544 | 0.98 | LTA4H (0.53) | LTA4HCYSLTR2CYSLTR1MAPTBRD4 | |
| SCHEMBL3267566 | 0.94 | BRD4 (0.54) | LTA4HCYSLTR2CYSLTR1MAPTBRD4 | |
| Hydrochloric Acid SCHEMBL31742267 | 0.92 | BRD4 (0.53) | LTA4HCYSLTR2CYSLTR1MAPTBRD4 | |
| SCHEMBL11956809 | 0.91 | GAA (0.47) | MAPTHTT | |
| SCHEMBL13933078 | 0.90 | NPC1 (0.60) | MAPTHTTTSHR | |
| SCHEMBL14570538 | 0.88 | MEN1 (0.59) | LTA4HCYSLTR2CYSLTR1MAPTBRD4 | |
| Hydrochloric Acid SCHEMBL8483256 | 0.88 | TSHR (0.52) | LTA4HCYSLTR2CYSLTR1TSHRTDP1 | |
| SCHEMBL17888566 | 0.87 | CYSLTR2 (0.49) | LTA4HCYSLTR2CYSLTR1MAPTBRD4 | |
| SCHEMBL19474670 | 0.86 | LTA4H (0.53) | LTA4HCYSLTR2CYSLTR1MAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170827-A2 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170827-A2 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20070269841-A1 | DETERMINATION OF CONCENTRATION OF FK778 BY COMPETITIVE IMMUNOASSAY | SPRING THOMAS G | 2007-11-22 | — | — | US | disclosed |
| US-20070243631-A1 | DETERMINATION OF CONCENTRATION OF FK778 BY COMPETITIVE IMMUNOASSAY | SPRING THOMAS G | 2007-10-18 | — | — | US | disclosed |
| US-7256008-B2 | Determination of concentration of FK778 by competitive immunoassay | ABBOTT LABORATORIES (US) | 2007-08-14 | — | — | US | disclosed |
| US-20070178544-A1 | Anti fk778antibodies and high sensitive immunoassay methods | TAMURA KOUICHI | 2007-08-02 | — | — | US | disclosed |
| US-20070161123-A1 | DETERMINATION OF CONCENTRATION OF FK778 BY COMPETITIVE IMMUNOASSAY | ABBOTT LABORATORIES | 2007-07-12 | — | — | US | disclosed |
| EP-1723179-A1 | ANTI FK778 ANTIBODIES AND HIGH SENSITIVE IMMUNOASSAY METHODS | Astellas Pharma Inc. (JP) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005085290-A1 | ANTI FK778ANTIBODIES AND HIGH SENSITIVE IMMUNOASSAY METHODS | ASTELLAS PHARMA INC. (JP) | 2005-09-15 | — | — | WO | disclosed |
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1283055-A1 | SOLUBLE BETA AMYLOID PRECURSOR PROTEIN SECRETION PROMOTERS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | APP, BDNF, BACE1 | LTA4H 2778/4885CYSLTR2 3439/4885CYSLTR1 3121/4885 |
| US-20070178544-A1 | Anti fk778antibodies and high sensitive immunoassay methods | LY96, FAM83B, FAM162A | LTA4H 1942/4885CYSLTR2 2968/4885CYSLTR1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.